AHA 2018 — AKCEA-APO(a)-L(RX) safely and effectively lowers Lp(a) levels in phase 2 trial

Lipoprotein(a) is an independent genetic risk factor for atherosclerotic cardiovascular disease and calcific aortic valve stenosis.